EUCTR2006-003746-42-IT
Active, not recruiting
Not Applicable
Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma - ND
OSPEDALE ONCOLOGICO DI BARI0 sites210 target enrollmentOctober 3, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- OSPEDALE ONCOLOGICO DI BARI
- Enrollment
- 210
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologic diagnosis of kidney carcinoma 2\. Presence of metastases and/or locally advanced primary tumour 3\. Age 18 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\. Severe infections 2\. Previous treatment with IL\-2 3\. Brain metastasis 4\. Pregnancy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Stereotactic Body Radiation in combination with immunotherapy-chemotherapy in patients with Metastatic Non-Small Cell Lung Cancer.Patients with both squamous and nonsquamous metastatic non-small cell lung cancer (NSCLC) wild type in EGFR, KRAS, ALK and ROS1.MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-002453-28-ITAZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA132
Completed
Not Applicable
Immunological aspects of combined chemotherapy and immunotherapy with HPV16 E6/E7 Synthetic Long Peptide vaccination in patients with advanced cervical cancer.cancer of the cervixcervical cancer10038594NL-OMON36470eids Universitair Medisch Centrum18
Completed
Phase 1
Phase I study of Chemo-Immunotherapy in patients with relapsed and refractory head and neck carcinomaHead and neck squamous cell carcinomaJPRN-UMIN000003725niversity of Yamanashi, Faculty of Medicine10
Active, not recruiting
Not Applicable
Randomised Study Comparing an Immuno-Chemotherapy with 6 Cycles of the Monoclonal anti-CD20 Antibody Rituximab in Combination with 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, both with or without consolidating Radiotherapy of Large Tumour Masses (≥ 7.5 cm) and/or Extranodal Involvement in Patients with Aggressive CD20+ B-Cell Lymphoma Aged 18 to 60 Years with Age-adjusted IPI=1 (all) or IPI=0 with Bulky Disease (≥ 7.5 cm) - UNFOLDEREUCTR2005-005218-19-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI1,072
Active, not recruiting
Phase 1
Randomised Study Comparing an Immuno-Chemotherapy with 6 Cyclesof the Monoclonal anti-CD20 Antibody Rituximab in Combination with6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine,and Prednisone) at 21-day Intervals or 14-day Intervals, both with or withoutconsolidating Radiotherapy of Large Tumour Masses (= 7.5 cm) and/orExtranodal involvement in Patients with Aggressive CD20+ B-Cell LymphomaAged 18 to 60 Years with Age-adjusted IPI=1 (all) or IPI=0 withBulky Disease (= 7.5 cm) Short Title: UNFOLDER 21/14 Study - UNFOLDER 21/14 studyPatients with untreated aggressive CD20+ Non-Hodgkin’s Lymphoma aged 18 to 60 years without major accompanying diseases with IPI= 1 (all) or IPI= 0 and bulky disease (=7.5cmEUCTR2005-005218-19-DKGerman High Grade Non-Hodgkin's Lymphoma group1,072